Table 1.
List of All Patients Included in the Study.
| Patient | Age, y | Sex | Scheduled follow-up, d | Actual follow-up, d | Pre- BCVA | BCVA after hemorrhage | Baseline BCVA, fellow eye | CNVM status pre–COVID-19, last injected agent |
Size >1 disc diameter | Hemorrhage thickness, μm | Prior OCT risk features | Prior hemorrhage | Duration of subjective change, d | Anticoagulation | COVID-19 systemic risks | Systemic vascular comorbidities | Spoke with physician about delaying follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 78 | F | 84 | 159 | 20/150 | 20/300 | 20/100 | Active, aflibercept | Yes | 944 | SHRM adjacent to active PED-CNVM | Yes | 60 | None | Asthma | HTN | No |
| 2 | 78 | M | 84 | 132 | 20/25 | CF 3 ft | 20/70 | Nonexudative | Yes | 1110 | Irregular PED with pigment | No | 90 | Asa 81 | COPD | HTN, OSA | No |
| 3 | 90 | M | 28 | 55 | 20/250 | CF 2 ft | 20/60 | Active, aflibercept | Yes | 46 | GA, shallow irregular PED | Yes | 3 | Asa 81, apixaban | Smoking/COPD | CAD/Afib | No |
| 4 | 97 | F | 240 | 268 | 20/30 | 20/70 | 20/70 | Nonexudative | No | 420 | Drusen, no signs of CNVM | No | 90 | Asa 81 | Asthma | HTN, heart block | No |
| 5 | 78 | M | 28 | 120 | 20/20 | 20/125 | 20/25 | Active, ranibizumab | No | 119 | Shallow irregular PED with pigment | Yes | 28 | Asa 81 | Diabetes | HTN, CAD | Yes |
| 6 | 83 | F | 63 | 103 | 20/25 | 20/40 | 20/100 | Active, aflibercept | No | 96 | Irregular PED adjacent to GA | Yes | 14 | Asa 81 | Mycophenolate mofetil for AI hepatitis | No | |
| 7 | 53 | F | 70 | 92 | 20/25 | 20/25 | 20/20 | Active, aflibercept | No | 90 | Active FCE-associated CNVM with SRF | Yes | 14 | None | None | No | |
| 8 | 86 | F | 42 | 137 | 20/70 | HM | 20/60 | Active, ranibizumab | Yes | 374 | Active CNVM, PED with SRF | No | – | Asa 81, clopidogrel | CHF, CKD4 | HTN, CAD | No |
| 9 | 96 | M | 63 | 116 | 20/100 | 10/125 | 20/300 | Active, aflibercept | Yes | 190 | Shallow irregular PED with pigment | No | 14 | Asa 81, clopidogrel | Smoking/COPD | Hx of AA s/p repair | No |
| 10 | 88 | M | 112 | 208 | CF 1 ft | CF 1 ft | 20/25 | Inactive | Yes | 360 | Disciform scar, irregular PED adjacent | Yes | – | Rivaroxaban | Smoking/CHF | CAD/Afib | No |
| 11 | 78 | F | 35 | 70 | 20/40 | 20/300 | 20/40 | Active, aflibercept | Yes | 528 | SHRM adjacent to active PED | No | 7 | None | Age only | No | |
| 12 | 86 | F | 180 | 201 | 20/100 | 20/150 | 20/200 | Nonexudative | No | 119 | Drusen, GA, no signs of CNVM | No | 1 | None | Smoking/COPD | No | |
| 13 | 70 | F | 42 | 210 | 20/150 | 20/150 | 20/25 | Active, aflibercept | No | 227 | Large, irregular PED (460-µm height) | Yes | 60 | None | Diabetes | No | |
| 14 | 90 | F | 49 | 188 | 20/50 | 20/200 | 20/25 | Active, aflibercept | No | 236 | Shallow, irregular PED | Yes | 30 | None | Smoking/COPD | No | |
| Mean | 82.2 ± 11.3 | 86.9 ± 66.8 | 147.1 ± 61.0 | ||||||||||||||
Abbreviations: AA, aortic aneurysm; Afib, atrial fibrillation; AI, autoimmune hepatitis; Asa, aspirin; BCVA, best-corrected visual acuity; CAD, coronary artery disease; CF, counting fingers; CHF, congestive heart failure; CKD, chronic kidney disease; CNVM, choroidal neovascular membrane; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; F, female; FCE, focal choroidal excavation; GA, geographic atrophy; HM, hand motion; HTN, hypertension; Hx, history; M, male; OCT, optical coherence tomography; OSA, obstructive sleep apnea; PED, pigment epithelial detachment; SHRM, subretinal hyperreflective material; s/p, status post; SRF, subretinal fluid.